Postmortem Cortical Transcriptomics of Lewy Body Dementia Reveal Mitochondrial Dysfunction and Lack of Neuroinflammation.
暂无分享,去创建一个
D. Aarsland | C. Ballard | Gareth Williams | P. Francis | A. Hye | G. Bidkhori | S. Shoaie | A. Rajkumar | H. Morrin | E. Clarke | Hamilton Morrin | Abdul Hye
[1] L. Stefanis,et al. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson’s disease dementia, dementia with Lewy bodies and Alzheimer’s disease , 2018, Journal of Neurology.
[2] Jens Nielsen,et al. Metabolic Network-Based Identification and Prioritization of Anticancer Targets Based on Expression Data in Hepatocellular Carcinoma , 2018, Front. Physiol..
[3] I. Ferrer,et al. Transcriptional network analysis in frontal cortex in Lewy body diseases with focus on dementia with Lewy bodies , 2018, Brain pathology.
[4] I. McKeith,et al. Molecular changes in the absence of severe pathology in the pulvinar in dementia with Lewy bodies , 2018, Movement disorders : official journal of the Movement Disorder Society.
[5] Sonja W. Scholz,et al. Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study , 2018, The Lancet Neurology.
[6] C. Taylor,et al. Regulation of immunity and inflammation by hypoxia in immunological niches , 2017, Nature Reviews Immunology.
[7] A. Martínez-Marcos,et al. &agr;-Synucleinopathy in the Human Amygdala in Parkinson Disease: Differential Vulnerability of Somatostatin- and Parvalbumin-Expressing Neurons , 2017, Journal of neuropathology and experimental neurology.
[8] D. Ffytche,et al. New Therapeutic Strategies for Lewy Body Dementias , 2017, Current Neurology and Neuroscience Reports.
[9] J. Freer. UK lags far behind Europe on diagnosis of dementia with Lewy bodies , 2017, British Medical Journal.
[10] Alan J. Thomas,et al. Diagnosis and management of dementia with Lewy bodies , 2017, Neurology.
[11] V. Turk,et al. Lysosomal cathepsins and their regulation in aging and neurodegeneration , 2016, Ageing Research Reviews.
[12] W. Sadee,et al. Gene expression profiling of brain samples from patients with Lewy body dementia. , 2016, Biochemical and biophysical research communications.
[13] G. Deuschl,et al. Abolishing the 1‐year rule: How much evidence will be enough? , 2016, Movement disorders : official journal of the Movement Disorder Society.
[14] W. Streit,et al. Microglia in dementia with Lewy bodies , 2016, Brain, Behavior, and Immunity.
[15] M. Stowell,et al. Exosomes and other extracellular vesicles in neural cells and neurodegenerative diseases. , 2016, Biochimica et biophysica acta.
[16] Paul Edison,et al. Neuroinflammation in Alzheimer's disease: Current evidence and future directions , 2016, Alzheimer's & Dementia.
[17] H. Kim,et al. IDH2 deficiency promotes mitochondrial dysfunction and dopaminergic neurotoxicity: implications for Parkinson’s disease , 2016, Free radical research.
[18] Jason J. Corneveaux,et al. Next-generation profiling to identify the molecular etiology of Parkinson dementia , 2016, Neurology: Genetics.
[19] J. O'Brien,et al. Exome sequencing in dementia with Lewy bodies , 2016, Translational Psychiatry.
[20] D. Aarsland,et al. Neurocognitive Deficits Distinguishing Mild Dementia with Lewy Bodies from Mild Alzheimer's Disease are Associated with Parkinsonism. , 2016, Journal of Alzheimer's disease : JAD.
[21] B. Boeve,et al. Lewy body dementias , 2015, The Lancet.
[22] D. Catalucci,et al. Neutrophils promote Alzheimer's disease–like pathology and cognitive decline via LFA-1 integrin , 2015, Nature Medicine.
[23] Qibin Li,et al. Experimental validation of methods for differential gene expression analysis and sample pooling in RNA-seq , 2015, BMC Genomics.
[24] B. Giometto,et al. The possible involvement of mitochondrial dysfunctions in Lewy body dementia: a systematic review. , 2015, Functional neurology.
[25] Janna H. Neltner,et al. Disease-related microglia heterogeneity in the hippocampus of Alzheimer’s disease, dementia with Lewy bodies, and hippocampal sclerosis of aging , 2015, Acta Neuropathologica Communications.
[26] Steven L Salzberg,et al. HISAT: a fast spliced aligner with low memory requirements , 2015, Nature Methods.
[27] B. Bogerts,et al. VGF expression by T lymphocytes in patients with Alzheimer's disease , 2015, Oncotarget.
[28] D. Dinsdale,et al. RBM3 mediates structural plasticity and protective effects of cooling in neurodegeneration , 2014, Nature.
[29] T. Hortobágyi,et al. Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias , 2014, Brain pathology.
[30] B. Mollenhauer,et al. Biomarkers in biological fluids for dementia with Lewy bodies , 2014, Alzheimer's Research & Therapy.
[31] B. Trapp,et al. Microglial displacement of inhibitory synapses provides neuroprotection in the adult brain , 2014, Nature Communications.
[32] W. M. van der Flier,et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies , 2014, Human molecular genetics.
[33] K. Ülgen,et al. Systematic analysis of transcription-level effects of neurodegenerative diseases on human brain metabolism by a newly reconstructed brain-specific metabolic network , 2014, FEBS open bio.
[34] D. Aarsland,et al. Long-Term Mortality in a Cohort of Home-Dwelling Elderly with Mild Alzheimer's Disease and Lewy Body Dementia , 2014, Dementia and Geriatric Cognitive Disorders.
[35] D. Aarsland,et al. The use and costs of formal care in newly diagnosed dementia: a three-year prospective follow-up study. , 2014, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[36] Y. Bordelon,et al. Dementia with Lewy Bodies , 2014, Seminars in Neurology.
[37] Wei Shi,et al. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..
[38] C. Laske,et al. Increased myeloperoxidase plasma levels in patients with Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.
[39] K. Chopra,et al. Granulocyte colony stimulating factor (GCSF) improves memory and neurobehavior in an amyloid-β induced experimental model of Alzheimer's disease , 2013, Pharmacology Biochemistry and Behavior.
[40] I. Nookaew,et al. Enriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methods , 2013, Nucleic acids research.
[41] Davis J. McCarthy,et al. Count-based differential expression analysis of RNA sequencing data using R and Bioconductor , 2013, Nature Protocols.
[42] Sean R. Davis,et al. NCBI GEO: archive for functional genomics data sets—update , 2012, Nucleic Acids Res..
[43] K. Wilhelmsen,et al. Serum Granulocyte Colony-Stimulating Factor and Alzheimer's Disease , 2012, Dementia and Geriatric Cognitive Disorders Extra.
[44] Jeffrey T. Leek,et al. A statistical approach to selecting and confirming validation targets in -omics experiments , 2012, BMC Bioinformatics.
[45] C. Cimino,et al. Pilot study of granulocyte-colony stimulating factor for treatment of Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.
[46] Jason A. Papin,et al. TIGER: Toolbox for integrating genome-scale metabolic models, expression data, and transcriptional regulatory networks , 2011, BMC Systems Biology.
[47] Jason A. Papin,et al. Functional integration of a metabolic network model and expression data without arbitrary thresholding , 2011, Bioinform..
[48] M. Heneka,et al. Distinct modulation of microglial amyloid β phagocytosis and migration by neuropeptidesi , 2010, Journal of Neuroinflammation.
[49] B. Hyman,et al. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease , 2004, Journal of neurochemistry.
[50] P. Hof,et al. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease , 2003, Acta Neuropathologica.